(CTVA) Corteva - Overview
Stock: Seed, Crop Protection
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.03% |
| Yield on Cost 5y | 2.13% |
| Yield CAGR 5y | 6.70% |
| Payout Consistency | 100.0% |
| Payout Ratio | 21.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.6% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 3.64 |
| Character TTM | |
|---|---|
| Beta | 0.622 |
| Beta Downside | 0.910 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.89% |
| CAGR/Max DD | 0.16 |
Description: CTVA Corteva January 28, 2026
Corteva Inc. (NYSE: CTVA) is a pure-play agriculture company that operates two core segments: Seed and Crop Protection. The Seed segment focuses on advanced germplasm and trait technologies that boost yield, stress tolerance, and nutritional quality, while also offering digital decision-support tools for farmers. The Crop Protection segment supplies herbicides, insecticides, nitrogen stabilizers, and pasture-range herbicides that defend crops from weeds, insects, and diseases and improve overall crop health.
According to Corteva’s FY 2025 Form 10-K (filed March 2026), total revenue reached $13.2 billion, a 4 % year-over-year increase driven primarily by the Seed segment, which generated $7.3 billion (≈55 % of total) and grew 6 % YoY on the back of 12 new trait launches and a 15 % rise in digital-solution subscriptions. The Crop Protection segment posted $5.9 billion in revenue, down 2 % YoY, reflecting softer herbicide pricing amid a global nitrogen price correction. External data from the International Fertilizer Association (IFA) shows global fertilizer demand is projected to expand at a 3 % CAGR through 2029, while climate-related yield volatility is increasing farmer adoption of resilient seed traits-both trends that support Corteva’s long-term growth narrative.
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed model on CTVA to see how these drivers translate into valuation outlooks.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 1.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.78 > 1.0 |
| NWC/Revenue: 29.94% < 20% (prev 27.86%; Δ 2.08% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.41b > Net Income 1.09b |
| Net Debt (-1.94b) to EBITDA (3.07b): -0.63 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (673.2m) vs 12m ago -2.06% < -2% |
| Gross Margin: 46.38% > 18% (prev 0.44%; Δ 4594 % > 0.5%) |
| Asset Turnover: 41.59% > 50% (prev 41.42%; Δ 0.18% > 0%) |
| Interest Coverage Ratio: 10.38 > 6 (EBITDA TTM 3.07b / Interest Expense TTM 180.0m) |
Altman Z'' 0.93
| A: 0.12 (Total Current Assets 17.34b - Total Current Liabilities 12.12b) / Total Assets 42.84b |
| B: -0.00 (Retained Earnings -67.0m / Total Assets 42.84b) |
| C: 0.04 (EBIT TTM 1.87b / Avg Total Assets 41.84b) |
| D: -0.15 (Book Value of Equity -2.86b / Total Liabilities 18.46b) |
| Altman-Z'' Score: 0.93 = BB |
Beneish M -3.22
| DSRI: 1.09 (Receivables 6.37b/5.68b, Revenue 17.40b/16.91b) |
| GMI: 0.94 (GM 46.38% / 43.64%) |
| AQI: 0.70 (AQ_t 0.37 / AQ_t-1 0.53) |
| SGI: 1.03 (Revenue 17.40b / 16.91b) |
| TATA: -0.05 (NI 1.09b - CFO 3.41b) / TA 42.84b) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of CTVA shares?
Over the past week, the price has changed by -0.82%, over one month by +3.51%, over three months by +11.03% and over the past year by +17.90%.
Is CTVA a buy, sell or hold?
- StrongBuy: 13
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CTVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.6 | 12.4% |
| Analysts Target Price | 81.6 | 12.4% |
| ValueRay Target Price | 76.7 | 5.6% |
CTVA Fundamental Data Overview February 09, 2026
P/E Forward = 20.3252
P/S = 2.8193
P/B = 2.0212
P/EG = 1.0647
Revenue TTM = 17.40b USD
EBIT TTM = 1.87b USD
EBITDA TTM = 3.07b USD
Long Term Debt = 1.69b USD (from longTermDebt, two quarters ago)
Short Term Debt = 894.0m USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.94b USD (from netDebt column, last quarter)
Enterprise Value = 47.11b USD (49.06b + Debt 2.58b - CCE 4.53b)
Interest Coverage Ratio = 10.38 (Ebit TTM 1.87b / Interest Expense TTM 180.0m)
EV/FCF = 16.73x (Enterprise Value 47.11b / FCF TTM 2.81b)
FCF Yield = 5.98% (FCF TTM 2.81b / Enterprise Value 47.11b)
FCF Margin = 16.18% (FCF TTM 2.81b / Revenue TTM 17.40b)
Net Margin = 6.29% (Net Income TTM 1.09b / Revenue TTM 17.40b)
Gross Margin = 46.38% ((Revenue TTM 17.40b - Cost of Revenue TTM 9.33b) / Revenue TTM)
Gross Margin QoQ = 38.29% (prev 37.20%)
Tobins Q-Ratio = 1.10 (Enterprise Value 47.11b / Total Assets 42.84b)
Interest Expense / Debt = 1.78% (Interest Expense 46.0m / Debt 2.58b)
Taxrate = 28.67% (484.0m / 1.69b)
NOPAT = 1.33b (EBIT 1.87b * (1 - 28.67%))
Current Ratio = 1.43 (Total Current Assets 17.34b / Total Current Liabilities 12.12b)
Debt / Equity = 0.11 (Debt 2.58b / totalStockholderEquity, last quarter 24.14b)
Debt / EBITDA = -0.63 (Net Debt -1.94b / EBITDA 3.07b)
Debt / FCF = -0.69 (Net Debt -1.94b / FCF TTM 2.81b)
Total Stockholder Equity = 24.89b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.62% (Net Income 1.09b / Total Assets 42.84b)
RoE = 4.40% (Net Income TTM 1.09b / Total Stockholder Equity 24.89b)
RoCE = 7.03% (EBIT 1.87b / Capital Employed (Equity 24.89b + L.T.Debt 1.69b))
RoIC = 4.57% (NOPAT 1.33b / Invested Capital 29.17b)
WACC = 7.86% (E(49.06b)/V(51.64b) * Re(8.21%) + D(2.58b)/V(51.64b) * Rd(1.78%) * (1-Tc(0.29)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.21%
[DCF Debug] Terminal Value 72.53% ; FCFF base≈2.31b ; Y1≈1.64b ; Y5≈869.3m
Fair Price DCF = 28.21 (EV 17.02b - Net Debt -1.94b = Equity 18.96b / Shares 672.2m; r=7.86% [WACC]; 5y FCF grow -34.24% → 2.90% )
EPS Correlation: -15.53 | EPS CAGR: -32.68% | SUE: 0.02 | # QB: 0
Revenue Correlation: -14.05 | Revenue CAGR: -4.25% | SUE: -1.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.17 | Chg30d=-0.010 | Revisions Net=+2 | Analysts=15
EPS current Year (2026-12-31): EPS=3.62 | Chg30d=-0.053 | Revisions Net=+3 | Growth EPS=+8.3% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=3.24 | Chg30d=-0.157 | Revisions Net=+1 | Growth EPS=+13.3% | Growth Revenue=+3.1%